This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Meyerowitz expanded this rhetoric through a series of publications that sought to reconstruct early history. She claimed that Akan origins and culture came from areas in the Sahara and the Near East, and argued that Akan culture was not mainly black African, but could instead be considered Libya-Berber or connected to Mediterranean or Near Eastern cultures.
== Activities == Verification of machinery and equipment usually consists of design qualification (DQ), installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ). DQ may be performed by a vendor or by the user, by confirming through review and testing that the equipment meets the written acquisition specification. If the relevant document or manuals of machinery/equipment are provided by vendors, the later 3Q needs to be thoroughly performed by the users who work in an industrial regulatory environment. Otherwise, the process of IQ, OQ and PQ is the task of validation. The typical example of such a case could be the loss or absence of vendor's documentation for legacy equipment or do-it-yourself (DIY) assemblies (e.g., cars, computers, etc.) and, therefore, users should endeavour to acquire DQ document beforehand. Each template of DQ, IQ, OQ and PQ usually can be found on the internet respectively, whereas the DIY qualifications of machinery/equipment can be assisted either by the vendor's training course materials and tutorials, or by the published guidance books, such as step-by-step series if the acquisition of machinery/equipment is not bundled with on- site qualification services. This kind of the DIY approach is also applicable to the qualifications of software, computer operating systems and a manufacturing process. The most important and critical task as the last step of the activity is to generating and archiving machinery/equipment qualification reports for auditing purposes, if regulatory compliances are mandatory.
=== Epilepsy === Tiagabine is approved by the United States Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures in epilepsy in individuals of age 12 and up. It is effective as monotherapy and combination therapy with other anticonvulsant drugs in the treatment of partial seizure.
Vaccines must be handled and transported according to international regulations, be maintained at controlled temperatures that vary across vaccine technologies, and be used for immunization before deterioration in storage. The scale of the COVID‑19 vaccine supply chain is expected to be vast to ensure delivery worldwide to vulnerable populations. Priorities for preparing facilities for such distribution include temperature-controlled facilities and equipment, optimizing infrastructure, training immunization staff, and rigorous monitoring. RFID technologies are being implemented to track and authenticate a vaccine dose from the manufacturer along the entire supply chain to the vaccination. In September 2020, Grand River Aseptic Manufacturing agreed with Johnson & Johnson to support the manufacture of its vaccine candidate, including technology transfer and fill and finish manufacturing. In October 2020, it was announced that the Moderna vaccine candidate will be manufactured in Visp, Switzerland by its partner Lonza Group, which plans to produce the first doses in December 2020. The newly built 2,000-square-metre facility will ramp up production to 300 million doses annually. The ingredient will be shipped frozen at −70 °C to Spain's Laboratorios Farmacéuticos Rovi SA for the final stage of manufacturing. Lonza's site in Portsmouth, New Hampshire, aimed to start making vaccine ingredients exclusively for the U.S. by November 2020.
=== Reality television === There are programs specifically dedicated to showcasing the lives and resulting struggles of people experiencing specific mental illnesses. For example, the hit television show on the A&E network, Hoarders, showcases one or two individuals and their obsessive-compulsive disorder. Throughout an episode, each individual works with a psychologist or psychiatrist, professional organizer, or an "extreme cleaning specialist" specializing in treating this disorder. Another program on the A&E network, Intervention, introduces audiences to people dealing with substance abuse. This program, in a similar format to Hoarders, follows the story of either one or two individuals who suffer from substance dependence. During an episode, the audience follows the individuals' daily lives and is introduced to the reality of living with this dependence. The individuals are then confronted with an ultimatum in which they must decide whether to seek rehabilitation or risk losing family, friends, shelter, and, in most cases, financial assistance. This documentary-style television program is valuable because it educates viewers about the entire intervention process, from being introduced to the intervention process itself to the proper way to handle an individual with addiction. It also effectively decreases the stigma of therapy and demonstrates the effectiveness of interventions.
Sources: en.wikipedia.org
== Vegetable biomass-based textiles == Polysaccharide-based polymers are made of fruit and vegetable origin, and the most promising biopolymer-yielding fibers include cellulose, starch, chitin/chitosan, pectin, alginate, and carrageenan. Soy, whey, and zein could also be obtained from vegetable sources. An example is Pinatex, a pineapple-based leather that is manufactured from the cellulose fibers of pineapple leaves. It is an environmentally friendly alternative to traditional leather due to its sustainability and adaptability. Additionally its lightweight, resilient and biodegradable nature has made it very popular for new and innovative fashion.
oxidized rubredoxin + NAD(P)H + H+ The 3 substrates of this enzyme are reduced rubredoxin, NAD+, and NADP+, whereas its 4 products are oxidized rubredoxin, NADH, NADPH, and H+. This enzyme belongs to the family of oxidoreductases, specifically those acting on iron-sulfur proteins as donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is rubredoxin:NAD(P)+ oxidoreductase. Other names in common use include rubredoxin-nicotinamide adenine dinucleotide (phosphate) reductase, rubredoxin-nicotinamide adenine, dinucleotide phosphate reductase, NAD(P)+-rubredoxin oxidoreductase, and NAD(P)H-rubredoxin oxidoreductase. This enzyme participates in fatty acid metabolism.
=== Covalent peptide tags === Isopeptag, a peptide which binds covalently to pilin-C protein (TDKDMTITFTNKKDAE) SpyTag, a peptide which binds covalently to SpyCatcher protein (AHIVMVDAYKPTK) SnoopTag, a peptide which binds covalently to SnoopCatcher protein (KLGDIEFIKVNK). A second generation, SnoopTagJr, was also developed to bind to either SnoopCatcher or DogTag (mediated by SnoopLigase) (KLGSIEFIKVNK) DogTag, a peptide which covalently binds to DogCatcher (DIPATYEFTDGKHYITNEPIPPK) and can react as an internal tag in loops of proteins. DogTag can also covalently bind to SnoopTagJr, mediated by SnoopLigase. SdyTag, a peptide which binds covalently to SdyCatcher protein (DPIVMIDNDKPIT). SdyTag/SdyCatcher has a kinetic-dependent cross-reactivity with SpyTag/SpyCatcher.
In a gravitational field, liquids exert pressure on the sides of a container as well as on anything within the liquid itself. Liquid pressure is transmitted in all directions and increases with depth. If a liquid is at rest in a uniform gravitational field, the pressure
== External links == Proprotein+Convertase+1 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P63239 (Mouse Neuroendocrine convertase 1) at the PDBe-KB.
Sources: en.wikipedia.org
Adversarial robustness is often associated with security. Researchers demonstrated that an audio signal could be imperceptibly modified so that speech-to-text systems transcribe it to any message the attacker chooses. Network intrusion and malware detection systems also must be adversarially robust since attackers may design their attacks to fool detectors. Models that represent objectives (reward models) must also be adversarially robust. For example, a reward model might estimate how helpful a text response is and a language model might be trained to maximize this score. Researchers have shown that if a language model is trained for long enough, it will leverage the vulnerabilities of the reward model to achieve a better score and perform worse on the intended task. This issue can be addressed by improving the adversarial robustness of the reward model. More generally, any AI system used to evaluate another AI system must be adversarially robust. This could include monitoring tools, since they could also potentially be tampered with to produce a higher reward. Large language models (LLMs) can be vulnerable to prompt injection and model stealing, and may be used to generate misinformation. Prompt injection involves embedding instructions into prompts in order to bypass safety measures. Some approaches against prompt injection use customizable policies and rules to analyze inputs and outputs, ensuring that potentially problematic interactions are filtered or mitigated.
A particular antibody often selects for a subpopulation of its target protein that has the epitope exposed, thus failing to identify any proteins in complexes that hide the epitope. This can be seen in that it is rarely possible to precipitate even half of a given protein from a sample with a single antibody, even when a large excess of antibody is used. As successive rounds of targeting and immunoprecipitations take place, the number of identified proteins may continue to grow. The identified proteins may not ever exist in a single complex at a given time, but may instead represent a network of proteins interacting with one another at different times for different purposes. Repeating the experiment by targeting different members of the protein complex allows the researcher to double-check the result. Each round of pull-downs should result in the recovery of both the original known protein as well as other previously identified members of the complex (and even new additional members). By repeating the immunoprecipitation in this way, the researcher verifies that each identified member of the protein complex was a valid identification. If a particular protein can only be recovered by targeting one of the known members but not by targeting other of the known members then that protein's status as a member of the complex may be subject to question.
Trump is the first president since Grover Cleveland in 1892 to win non-consecutive terms. 2024 also marked the first time since 1892 that the incumbent party had lost in each of three consecutive presidential elections. This was the first time since 1980 that the Democrats were voted out after a single four-year term. This was also the second consecutive election in which the incumbent party had lost after a single four-year term. Trump is the first Republican to win the popular vote since George W. Bush's election in 2004; Bush and Trump are also the only two presidents who won the Electoral College while losing the popular vote in one election who then went on to win both the Electoral College and the popular vote in a subsequent election. Trump is also the first non-incumbent Republican to have won the popular vote since George H. W. Bush in 1988. Trump won a 1.48% margin of victory. While winning the popular vote, Trump did not win a majority of the popular vote; he is the first winning presidential candidate since Bill Clinton in 1996 to win the popular vote with a plurality and also the first Republican since Richard Nixon in 1968 to do so. After Cleveland in 1884 and 1892, Woodrow Wilson in 1912 and 1916, and Clinton in 1992 and 1996, Trump became the fourth president since 1880 to win two presidential elections and receive less than 50% of the popular vote in both presidential election victories. Trump is the first presidential candidate since Barack Obama in 2012 to win a second term in the White House and also the first Republican since George W.
=== Medieval modifications === Thomas Aquinas emphasized the act/potency understanding of form/matter whereby form activates the potency of matter and existence activates souls. The angels are accordingly composites of esse (potentiality) and existence (actuality) that activates immaterial souls, while God alone is per se existence, pure act without any potencies. Medieval theologians, newly exposed to Aristotle's philosophy, applied hylomorphism to Christian doctrines such as the transubstantiation of the Eucharist's bread and wine into the body and blood of Jesus. Theologians such as Duns Scotus and Thomas Aquinas developed Christian applications of hylomorphism. Aristotle's texts on the agent intellect have given rise to diverse interpretations. Some following Averroes (Ibn Rushd 1126–1198) argue that Aristotle equated the active intellect with a divine being who infuses concepts into the passive intellect to aid human understanding. Others following Aquinas (1225–74) argue that the Neoplatonic interpretation is a mistake: the active intellect is actually part of the human soul.
The kraken is a legendary sea monster of giant proportions said to dwell off the coasts of Norway and Greenland, usually portrayed in art as a giant cephalopod attacking ships. Linnaeus included it in the first edition of his 1735 Systema Naturae. In a Hawaiian creation myth that says the present cosmos is the last of a series which arose in stages from the ruins of the previous universe, the octopus is the lone survivor of the previous, alien universe. The Akkorokamui is a gigantic tentacled monster from Ainu folklore. A battle with an octopus plays a significant role in Victor Hugo's book Travailleurs de la mer (Toilers of the Sea), relating to his time in exile on Guernsey. Ian Fleming's 1966 short story collection Octopussy and The Living Daylights, and the 1983 James Bond film were partly inspired by Hugo's book. Japanese erotic art, shunga, includes ukiyo-e woodblock prints such as Katsushika Hokusai's 1814 print Tako to ama (The Dream of the Fisherman's Wife), in which an ama diver is sexually intertwined with a large and a small octopus. The print is a forerunner of tentacle erotica. Its many arms that emanate from a common center means that the octopus is sometimes used to symbolize a powerful and manipulative organization.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.